PMID- 23608451
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20130423
IS  - 1879-1131 (Electronic)
IS  - 0738-081X (Linking)
VI  - 31
IP  - 3
DP  - 2013 May-Jun
TI  - What's new in prognostication of melanoma in the dermatopathology laboratory?
PG  - 317-23
LID - S0738-081X(12)00177-0 [pii]
LID - 10.1016/j.clindermatol.2012.08.007 [doi]
AB  - With the advent of genetic and epigenetic research, molecular techniques could 
      someday be used to discriminate nevus from melanoma so that ambiguous melanocytic 
      lesions could be more accurately classified or that prognostication could be 
      improved in melanoma patients. That promised day might be closer than realized. 
      The last 20 years of research in cytogenetic and genetic alterations in melanoma 
      have culminated in defined chromosomal lesions discriminating benign from 
      malignant melanocytic tumors. Exploiting these differences, fluorescence in situ 
      hybridization (FISH) can reproducibly discriminate unequivocal melanomas from 
      melanocytic nevi with high sensitivity and specificity. The discriminating power 
      of FISH in melanocytic tumors with ambiguous histopathology is questionable, 
      however, because there is no standard definition of "malignancy." Additional FISH 
      studies on ambiguous cases are needed through international collaborations where 
      large collections of such cases are shared and the "proof of malignancy" is 
      established by adequate clinical follow-up. This contribution reviews the 
      diagnostic utility of DNA-based FISH technology as it compares the diagnostic 
      accuracy in melanocytic tumors with unambiguous vs ambiguous histopathology. The 
      melanoma epigenome is further characterized through research into various 
      activities of small interfering RNAs, such as microRNAs, providing the pathway 
      for the application of microRNA-based strategies that could be the basis for 
      future diagnostic biomarkers and molecular therapies in melanoma.
CI  - Published by Elsevier Inc.
FAU - Bangash, Haider K
AU  - Bangash HK
AD  - Department of Internal Medicine, University of Connecticut Health Center, 
      Farmington, CT 06032, USA.
FAU - Romegialli, Alison
AU  - Romegialli A
FAU - Dadras, Soheil S
AU  - Dadras SS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Dermatol
JT  - Clinics in dermatology
JID - 8406412
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Chromosome Aberrations
MH  - DNA, Neoplasm/genetics
MH  - Epigenomics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Melanoma/*diagnosis/genetics
MH  - Prognosis
MH  - Sensitivity and Specificity
MH  - Skin Neoplasms/*diagnosis/genetics
EDAT- 2013/04/24 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/24 06:00 [entrez]
PHST- 2013/04/24 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - S0738-081X(12)00177-0 [pii]
AID - 10.1016/j.clindermatol.2012.08.007 [doi]
PST - ppublish
SO  - Clin Dermatol. 2013 May-Jun;31(3):317-23. doi: 
      10.1016/j.clindermatol.2012.08.007.